Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: REFRESH LIQUIGEL® Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare a New Eye Drop Formulation With Refresh Contacts®

NCT01844388
View directory record Official record
Conditions
Contact Lens Lubrication
Interventions
carboxymethylcellulose based eye drop formula, carboxymethylcellulose sodium based eye drop solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Bloomington, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Altrazeal™ Versus Aquacel® Ag for Partial Thickness Skin Donor Sites

NCT01062204
View directory record Official record
Conditions
Partial-thickness Skin Donor Sites
Interventions
Altrazeal, Aquacel Ag
Device
Lead sponsor
ULURU Inc.
Industry
Eligibility
3 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

NCT01010282
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Glycerin and Polysorbate 80 based artificial tear, Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

NCT00544713
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Acceptability of Two Lubricant Eye Drops

NCT00756678
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Lubricant Eye Drops (Optive™), Lubricating Eye Drops (blink® Tears)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chevy Chase, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2011 · Synced Sep 28, 2026, 9:38 AM EDT
Not listed Phase 2 Interventional

Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome

NCT01544283
View directory record Official record
Conditions
Shoulder Pain
Interventions
Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide
Drug
Lead sponsor
Injury Care Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

NCT02280473
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive® Gel Drops, REFRESH LIQUIGEL®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Petaluma, California • San Diego, California • Bangor, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief

NCT02455050
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Sodium Based Eye Drops, Systane® Gel Drops, Genteal® Lubricant Gel Drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 28, 2026, 9:38 AM EDT
Withdrawn Not applicable Interventional

Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

NCT02517931
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Sphenopalatine Ganglion Block, Placebo
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear

NCT00691197
View directory record Official record
Conditions
Ametropia
Interventions
Carboxymethylcellulose sodium and Glycerin, Carboxymethylcellulose sodium
Device
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

NCT01079741
View directory record Official record
Conditions
Melanoma
Interventions
NY-ESO-1 protein; Poly-ICLC; Montanide
Biological
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 28, 2026, 9:38 AM EDT
Recruiting Phase 2 Interventional

Cabozantinib for Patients With Recurrent or Progressive Meningioma

NCT05425004
View directory record Official record
Conditions
Meningioma
Interventions
Cabozantinib
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01996826
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
10
States / cities
Azusa, California • Burbank, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 28, 2026, 9:38 AM EDT
Recruiting Phase 2 Interventional

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

NCT06343077
View directory record Official record
Conditions
Prostate Cancer Patients on Active Surveillance
Interventions
Poly-ICLC intramuscular (IM) injection, Poly-ICLC, Intertumoral (IT) injection
Drug
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

NCT04302896
View directory record Official record
Conditions
Medication Adherence, HIV
Interventions
dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
Drug
Lead sponsor
Rhonda Brand
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

NCT01459588
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Eye Drop Formulation B, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops, Carboxymethylcellulose Based Lubricant Eye Drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 28, 2026, 9:38 AM EDT
Recruiting Phase 2 Interventional

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Autologous alpha-DC1/TBVA vaccine, Cabozantinib
Biological · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 28, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 28, 2026, 9:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

NCT01720836
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Vaccine + PolyICLC
Biological
Lead sponsor
Olivera Finn
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 28, 2026, 9:38 AM EDT
Recruiting Phase 4 Interventional

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

NCT07676084
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 9:38 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds

NCT06984835
View directory record Official record
Conditions
Nasolabial Folds
Interventions
Ellanse S, Calcium Hydroxylapatite-based filler
Device
Lead sponsor
AQTIS Medical B.V.
Other
Eligibility
22 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Encino, California • Westport, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 28, 2026, 9:38 AM EDT